Detalhe da pesquisa
1.
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.
N Engl J Med
; 387(25): 2317-2330, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546624
2.
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.
Acta Derm Venereol
; 104: adv13467, 2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38348724
3.
A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis.
Pediatr Dermatol
; 41(2): 204-209, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38308453
4.
Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis.
Pharm Res
; 40(11): 2653-2666, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38082089
5.
Disease Burden and Unmet Need in Eosinophilic Esophagitis.
Am J Gastroenterol
; 117(8): 1231-1241, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35417421
6.
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
Clin Exp Allergy
; 51(7): 915-931, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34037993
7.
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
Acta Derm Venereol
; 101(11): adv00585, 2021 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34618162
8.
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
N Engl J Med
; 377(3): 211-221, 2017 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28538136
9.
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
J Am Acad Dermatol
; 83(5): 1282-1293, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32574587
10.
Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
J Am Acad Dermatol
; 80(1): 158-167.e1, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30092324
11.
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
J Drugs Dermatol
; 18(8): 804-813, 2019 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31424712
12.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Lancet
; 389(10086): 2287-2303, 2017 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28478972
13.
Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial.
J Am Acad Dermatol
; 84(2): 495-497, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32387659
14.
Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
Adv Ther
; 41(3): 1046-1061, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194047
15.
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study.
Dermatol Ther (Heidelb)
; 13(9): 2107-2120, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552431
16.
Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks.
Dermatol Ther (Heidelb)
; 12(1): 223-231, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34806137
17.
Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study.
J Dermatolog Treat
; 33(3): 1608-1616, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33557637
18.
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment.
Dermatol Ther (Heidelb)
; 12(1): 195-202, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34897582
19.
Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis.
J Allergy Clin Immunol Pract
; 10(5): 1279-1285.e1, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35032695
20.
Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data.
Clin Pharmacol Drug Dev
; 10(11): 1345-1357, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34159738